OliX Pharmaceuticals, Inc (KOSDAQ: 226950)

OliX Pharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	6,091	11,983	4,930	34,337	11,329	4,954
Short-Term Investments	11,500	10,000	53,000	15,000	55,000	15,000
Trading Asset Securities	6,853	3,942	3,941	420.68	1,782	15,586
Cash & Short-Term Investments	24,444	25,925	61,872	49,757	68,111	35,540
Cash Growth	-42.23%	-58.10%	24.35%	-26.95%	91.64%	-24.47%
Accounts Receivable	0	3,558	53.23	-	-	-
Other Receivables	2,483	1,419	996.88	272.13	159.18	209.85
Receivables	2,483	4,977	1,050	491.49	446.57	409.85
Inventory	793.09	468.41	657.17	374.13	304.17	365.82
Prepaid Expenses	458.44	244.9	1,367	1,480	7.13	22.83
Other Current Assets	119.71	526.86	99	136.92	178.26	1,101
Total Current Assets	28,299	32,142	65,046	52,240	69,047	37,440
Property, Plant & Equipment	48,105	43,910	37,232	31,525	6,180	5,911
Long-Term Investments	12,408	23,481	26,809	0.5	0.45	0
Other Intangible Assets	1,786	1,981	2,107	2,134	2,529	1,411
Other Long-Term Assets	1,903	1,312	1,458	772.05	820.53	445.69
Total Assets	92,502	102,825	132,651	86,672	78,577	45,207
Accrued Expenses	344.14	465.36	358.62	297.85	80.04	24.91
Current Portion of Long-Term Debt	1,429	-	19,230	16,405	-	-
Current Portion of Leases	1,107	1,065	939.87	487.8	258.63	15.68
Other Current Liabilities	11,543	5,033	19,014	23,174	4,150	2,714
Total Current Liabilities	31,268	6,563	39,543	40,365	4,488	2,754
Long-Term Debt	25,750	35,362	20,000	20,326	14,011	-
Long-Term Leases	2,613	2,930	3,826	51.69	257	206.94
Long-Term Deferred Tax Liabilities	-	-	-	-	1,647	-
Other Long-Term Liabilities	6,474	7,634	3,080	6,296	12,597	293.75
Total Liabilities	66,105	52,489	66,449	67,265	33,227	3,400
Common Stock	8,318	8,010	6,852	6,852	6,771	3,265
Additional Paid-In Capital	160,286	157,177	151,895	92,908	91,128	71,540
Retained Earnings	-140,900	-122,910	-103,224	-84,303	-54,379	-34,799
Comprensive Income & Other	-2,089	7,141	8,885	3,064	1,765	1,792
Total Common Equity	25,615	49,418	64,407	18,521	45,286	41,798
Minority Interest	566.85	481.45	295.16	886.27	65.31	9.04
Shareholders' Equity	26,397	50,336	66,203	19,407	45,351	41,807
Total Liabilities & Equity	92,502	102,825	132,651	86,672	78,577	45,207
Total Debt	47,743	39,357	43,996	37,271	14,527	222.61
Net Cash (Debt)	-23,299	-13,433	17,876	12,487	53,584	35,318
Net Cash Growth	-	-	43.16%	-76.70%	51.72%	-24.95%
Net Cash Per Share	-1472.53	-930.93	1304.50	912.36	4074.15	2712.24
Filing Date Shares Outstanding	16.64	16.02	13.7	13.7	13.54	13.06
Total Common Shares Outstanding	16.64	16.02	13.7	13.7	13.54	13.06
Working Capital	-2,969	25,578	25,502	11,874	64,559	34,685
Book Value Per Share	1539.68	3084.79	4700.19	1351.59	3344.07	3200.42
Tangible Book Value	23,828	47,437	62,300	16,387	42,756	40,388
Tangible Book Value Per Share	1432.31	2961.16	4546.39	1195.84	3157.30	3092.41
Land	25,015	25,740	25,740	25,740	988.21	988.21
Buildings	1,218	3,354	3,354	3,354	3,115	3,115
Machinery	6,648	6,436	5,518	4,427	3,330	2,578
Construction In Progress	16,356	8,948	1,239	71.73	-	185.47

Source: S&P Capital IQ. Standard template. Financial Sources.